Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer (PanCAN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02967770|
Recruitment Status : Withdrawn (Issues with patient recruitment.)
First Posted : November 18, 2016
Last Update Posted : September 11, 2018
Thomas Jefferson University
Sinai Health System
Virginia Mason Hospital/Medical Center
Cedars-Sinai Medical Center
George Mason University
Caris Life Sciences, Inc
Theranostics Health, Inc
Guardant Health, Inc.
Companion Diagnostics, Inc.
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Recruitment Status :||Withdrawn|
|Actual Primary Completion Date :||August 30, 2018|
|Actual Study Completion Date :||August 30, 2018|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. J Pancreat Cancer. 2019 May 2;5(1):12-21. doi: 10.1089/pancan.2019.0003. eCollection 2019.